Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 2Unknown 1Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Prostatic Neoplasms 697Urinary Bladder Neoplasms 256Carcinoma, Renal Cell 190Kidney Neoplasms 94Neoplasms 72Carcinoma, Transitional Cell 69Breast Neoplasms 66Lung Neoplasms 38Ovarian Neoplasms 37Melanoma 37Colorectal Neoplasms 37Stomach Neoplasms 36Non-Muscle Invasive Bladder Neoplasms 35Neoplasm Metastasis 33Pancreatic Neoplasms 31Carcinoma, Non-Small-Cell Lung 29Recurrence 26Colonic Neoplasms 25Uterine Cervical Neoplasms 20Urologic Neoplasms 20Testicular Neoplasms 20Esophageal Neoplasms 20Liver Neoplasms 18Head and Neck Neoplasms 18Disease 18Wilms Tumor 17Carcinoma, Hepatocellular 17Endometrial Neoplasms 16Sarcoma 15Prostatic Hyperplasia 15

Interventions

repaglinide 1Bupropion 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Unknown × Prostate Cancer Patients × Genitourinary × Clear all
NCT04664725 2020-12-11

Drug-drug Interaction of SHR3680 With Repaglinide and Bupropion

Jiangsu HengRui Medicine Co., Ltd.

Phase 1 Unknown
18 enrolled
Genitourinary

Prostate Cancer Patients

Data powered by HemOnc (CC BY 4.0) Colophon âš¡